secwatch.observer — SEC 8-K summary
======================================

Issuer:     Praxis Precision Medicines, Inc. (PRAX)
CIK:        0001689548
Form:       8-K
Filed at:   2025-02-28T23:59:59+00:00
Accession:  0001689548-25-000037
Event type: other_material
Sentiment:  negative
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Praxis Essential3 interim analysis recommends futility; studies continue to Q3 2025
--------------------------------------------------------------------------------

- IDMC recommended stopping Essential3 Study 1 for futility; Praxis continues both studies to completion.
- Topline results for Essential3 now expected Q3 2025; NDA decision after final data.
- Cash, equivalents and marketable securities of $469.5M as of Dec 31, 2024, up from $81.3M.
- Net loss for Q4 2024 was $58.7M vs. $26.9M in Q4 2023; R&D spend rose to $56.3M from $18.4M.
- UCB exercised option to in-license KCNT1 candidate; Praxis eligible for up to ~$100M in milestones plus royalties.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000037/0001689548-25-000037-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689548/000168954825000037/prax-20250228.htm
  HTML page:      https://secwatch.observer/filing/0001689548-25-000037

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer